Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Misses on EPS, Stock Up 3.98%

Alnylam Pharmaceuticals reported a loss that was worse than expected, which typically raises concerns among investors. However, the stock still rose by nearly 4% following the announcement, suggesting that investors may have found some positive aspects in the overall performance or future potential. The lack of guidance and details from the earnings call leaves uncertainty about the company's direction.